Spyre Therapeutics Statistics Share Statistics Spyre Therapeutics has 60.4M
shares outstanding. The number of shares has increased by 18.53%
in one year.
Shares Outstanding 60.4M Shares Change (YoY) 18.53% Shares Change (QoQ) 0.16% Owned by Institutions (%) 16.79% Shares Floating 46.74M Failed to Deliver (FTD) Shares 1,254 FTD / Avg. Volume 0.22%
Short Selling Information The latest short interest is 13.78M, so 22.82% of the outstanding
shares have been sold short.
Short Interest 13.78M Short % of Shares Out 22.82% Short % of Float 29.29% Short Ratio (days to cover) 28.53
Valuation Ratios The PE ratio is -5.26 and the forward
PE ratio is -4.77.
Spyre Therapeutics's PEG ratio is
0.05.
PE Ratio -5.26 Forward PE -4.77 PS Ratio 0 Forward PS 9964.2 PB Ratio 2.11 P/FCF Ratio -6.96 PEG Ratio 0.05
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Spyre Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 11.26,
with a Debt / Equity ratio of 0.
Current Ratio 11.26 Quick Ratio 11.26 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-2.85M Employee Count 73 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 51K Effective Tax Rate -0.02%
Stock Price Statistics The stock price has increased by -43% in the
last 52 weeks. The beta is 2.88, so Spyre Therapeutics's
price volatility has been higher than the market average.
Beta 2.88 52-Week Price Change -43% 50-Day Moving Average 16.4 200-Day Moving Average 17.82 Relative Strength Index (RSI) 51.45 Average Volume (20 Days) 573,677
Income Statement
Revenue n/a Gross Profit n/a Operating Income -208.57M Net Income -208.02M EBITDA -207.97M EBIT -207.97M Earnings Per Share (EPS) -0.56
Full Income Statement Balance Sheet The company has 89.42M in cash and 0 in
debt, giving a net cash position of 89.42M.
Cash & Cash Equivalents 89.42M Total Debt n/a Net Cash n/a Retained Earnings -972.43M Total Assets 538.83M Working Capital 455.77M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -157.41M
and capital expenditures 0, giving a free cash flow of -157.41M.
Operating Cash Flow -157.41M Capital Expenditures n/a Free Cash Flow -157.41M FCF Per Share -3.35
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields SYRE does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for SYRE is $65,
which is 300.2% higher than the current price. The consensus rating is "Buy".
Price Target $65 Price Target Difference 300.2% Analyst Consensus Buy Analyst Count 6
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 8, 2023. It was a
backward
split with a ratio of 1:25.
Last Split Date Sep 8, 2023 Split Type backward Split Ratio 1:25
Scores Altman Z-Score 3.57 Piotroski F-Score 1
